iBio (NYSE:IBIO) Upgraded at StockNews.com

StockNews.com upgraded shares of iBio (NYSE:IBIO) to a sell rating in a research report sent to investors on Tuesday morning.

iBio Stock Performance

Shares of NYSE:IBIO opened at $4.56 on Tuesday. The company has a 50 day moving average of $3.92 and a two-hundred day moving average of $2.94. iBio has a 52-week low of $1.07 and a 52-week high of $6.89. The company has a quick ratio of 1.76, a current ratio of 1.76 and a debt-to-equity ratio of 0.05.

Insider Activity at iBio

In other news, Director David Arkowitz acquired 18,382 shares of the firm’s stock in a transaction on Friday, January 10th. The stock was bought at an average cost of $2.72 per share, with a total value of $49,999.04. Following the transaction, the director now directly owns 18,382 shares in the company, valued at approximately $49,999.04. This represents a ∞ increase in their position. The acquisition was disclosed in a legal filing with the SEC, which can be accessed through this link. Company insiders own 0.58% of the company’s stock.

Institutional Inflows and Outflows

An institutional investor recently raised its position in iBio stock. Geode Capital Management LLC boosted its holdings in shares of iBio, Inc. (NYSE:IBIO) by 52.3% during the 4th quarter, according to its most recent 13F filing with the Securities & Exchange Commission. The fund owned 83,797 shares of the company’s stock after purchasing an additional 28,775 shares during the quarter. Geode Capital Management LLC owned approximately 0.85% of iBio worth $205,000 at the end of the most recent quarter. Institutional investors own 7.90% of the company’s stock.

iBio Company Profile

iBio, Inc, a biotechnology company, engages in the development of precision antibodies in the United States. It offers IBIO-100, a preclinical anti-fibrotic program for the treatment of systemic scleroderma and idiopathic pulmonary fibrosis; and EngageTx platform, which provides an optimized CD3 T-cell engager antibody panel.